What's in Abbisko Therapeutics Co, Ltd's pipeline?

Abbisko Therapeutics Co, Ltd has 20 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 4 in Phase 2, 15 in Phase 1.

Which companies overlap with Abbisko Therapeutics Co, Ltd's portfolio?

Top competitors by shared drug class: Suzhou Abogen Biosciences Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/abbisko-therapeutics-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Abbisko Therapeutics Co, Ltd — Portfolio Competitive Intelligence Brief

Abbisko Therapeutics Co, Ltd pipeline: 0 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 4 Phase 2 15 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Pimicotinib(ABSK021)	Pimicotinib(ABSK021)	phase 3	HER2 tyrosine kinase inhibitor	HER2	Oncology

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Suzhou Abogen Biosciences Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Abbisko Therapeutics Co, Ltd:

Cite this brief

Drug Landscape (2026). Abbisko Therapeutics Co, Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/abbisko-therapeutics-co-ltd. Accessed 2026-05-16.